Recent Updates
Recently added Catalysts
QURE Negative Sentiment Score: 25/100

UNIQURE N.V. (QURE) INVESTOR ALERT Investors With Large Losses in uniQure N.V. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Key Takeaway: A shareholder has initiated a class action lawsuit against uniQure N.V. on behalf of investors who acquired its shares between September 24, 2025, and October 31, 2025. The lawsuit alleges that the company made false representations about AMT-130, a drug aimed at treating Huntington's Disease. Investors are being encouraged to take action by filing as lead plaintiffs by April 13, 2026, although they can still participate in any recovery as absent class members. Bernstein Liebhard LLP, the law firm handling the case, operates on a contingency basis, meaning no fees are charged to shareholders upfront.

Market Sentiment Analysis

CONCERNS & RISKS

  • Shareholder filed a class action lawsuit due to alleged misrepresentations.
  • Defendants are accused of misleading investors regarding the drug AMT-130.
  • Investors may experience significant losses related to the lawsuit.

Full Press Release Details

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the ordinary shares of uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE) between September 24, 2025 and October 31, 2025, inclusive.
For more information, submit a form at uniQure N.V. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or call us at (212) 951-2030.
If you wish to serve as lead plaintiff for the Class, you must file papers by April 13, 2026. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
According to the lawsuit, Defendants made misrepresentations concerning AMT-130, a drug the Company was developing for treatment of Huntington’s Disease.
About Bernstein Liebhard:
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
ATTORNEY ADVERTISING. © 2026 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Investor Relations Manager
Bernstein Liebhard LLP

Tags

uniqure class action

Frequently Asked Questions

What is the uniQure class action lawsuit about?

The lawsuit alleges misrepresentations by uniQure regarding AMT-130, a Huntington’s Disease treatment.

Who can file to be the lead plaintiff?

Anyone wishing to be lead plaintiff must file papers by April 13, 2026.

Do shareholders incur costs for representation?

No, all representation is on a contingency fee basis; shareholders pay no fees.

How do I contact Bernstein Liebhard LLP for more info?

You can contact them via email at pallocco@bernlieb.com or call (212) 951-2030.

What is the timeframe for the class action shares?

The class action involves shares purchased between September 24 and October 31, 2025.

Last updated: Feb 17, 2026